| Smith, Karen |
KEYNOTE B84, NCT04815720: Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
|
|
| Completed | 1/2 | 49 | US | pepinemab + pembrolizumab, KEYTRUDA® | Vaccinex Inc., Merck Sharp & Dohme LLC | Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) | 07/24 | 07/24 | | |
|
NCT04482140: Post Approval Study to Evaluate the Safety and Performance of GENTA-FOIL Resorb® in Hand Surgery |
|
|
| Recruiting | N/A | 55 | Europe | Genta-Foil resorb® | Advanced Medical Solutions Ltd., Newcastle-upon-Tyne Hospitals NHS Trust, KAT General Hospital | Tissue Adhesions, Surgery-Induced | 10/25 | 10/26 | | |
AIDI, NCT05713266: Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID |
|
|
| Completed | N/A | 204 | US | MouthLabTM | Edith Nourse Rogers Memorial Veterans Hospital, AIDAR Health, Inc., Biomedical Advanced Research and Development Authority | COVID-19, Long COVID | 01/24 | 02/24 | | |
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 1050 | Europe, US | Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay | Razor Genomics, Encore Clinical | Non-Small Cell Lung Cancer | 05/27 | 05/27 | | |
| Recruiting | N/A | 17000 | US | MCED, SOC | GRAIL, LLC | Early Detection of Cancer, Cancer | 06/25 | 08/26 | | |
| Active, not recruiting | N/A | 10 | Europe, Canada, US | Braive™ Growth Modulation System (Braive™ GMS) | Medtronic Spinal and Biologics, Medical Metrics Diagnostics, Inc | Juvenile Idiopathic Scoliosis, Adolescent Idiopathic Scoliosis | 12/24 | 12/29 | | |
| Recruiting | N/A | 7600 | Canada | XPERIENCE Advanced Surgical Irrigation, XP, Dilute Betadine, DB, Providone-Iodine | Ottawa Hospital Research Institute, Next Science TM | Hip Osteoarthritis, Hip Arthritis, Knee Osteoarthritis, Knee Arthritis | 03/27 | 12/27 | | |
| Bowlus, Christopher L |
| Active, not recruiting | 3 | 238 | Europe, Canada, Japan, US, RoW | Linerixibat, Placebo | GlaxoSmithKline | Pruritus | 10/24 | 01/25 | | |
| Recruiting | 3 | 251 | Europe, Canada, Japan, US, RoW | Linerixibat | GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited | Cholestasis | 02/27 | 02/27 | | |
| Active, not recruiting | 2 | 60 | US | Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo | Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc. | Primary Biliary Cholangitis | 11/24 | 02/25 | | |
| Active, not recruiting | 2 | 68 | Europe, US, RoW | Anti-human CCL24 monoclonal antibody (CM-101), Placebo | ChemomAb Ltd., ChemomAb Ltd | Primary Sclerosing Cholangitis | 09/24 | 09/25 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC |
|
|
| Not yet recruiting | 2 | 87 | US | LB-P8 low-dose, LB-P8 high-dose, Placebo | LISCure Biosciences | Primary Sclerosing Cholangitis (PSC) | 03/28 | 02/29 | | |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/26 | 11/26 | | |
| Active, not recruiting | 2 | 271 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | 12/25 | 03/26 | | |
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis |
|
|
| Active, not recruiting | 1/2 | 42 | US | CNP-104, Placebo | COUR Pharmaceutical Development Company, Inc. | Primary Biliary Cholangitis | 01/26 | 01/26 | | |
| Wong, Michael |
NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine |
|
|
| Not yet recruiting | 3 | 9320 | RoW | CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, COVID-19 and influenza combination, Novavax COVID-19 Vaccine, Novavax SARS-CoV-2 rS vaccine, tNIV Vaccine, Trivalent Nanoparticle Influenza Hemagglutinin Vaccine, Fluzone High Dose, Fluzone HD | Novavax | COVID-19 | 02/25 | 02/26 | | |
NCT06281678: A Study of IBI363 in Subjects with Advanced Solid Malignancies |
|
|
| Recruiting | 2 | 178 | US | IBI363 | Innovent Biologics (Suzhou) Co. Ltd. | Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer | 03/26 | 12/26 | | |
| Active, not recruiting | 2 | 77 | Europe, Canada, US | SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin | Seagen Inc., Merck Sharp & Dohme LLC | Melanoma, Carcinoma, Non-Small- Cell Lung | 01/24 | 10/25 | | |
| Recruiting | 2 | 340 | Europe, US | RP1, nivolumab, Opdivo | Replimune Inc., Bristol-Myers Squibb | Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC | 12/25 | 12/28 | | |
|
|
|
NCT06680128: A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults |
|
|
| Not yet recruiting | 1/2 | 402 | RoW | GBP560-A, GBP560-B, IXIARO, IMOJEV, Normal Saline (Placebo) | SK Bioscience Co., Ltd. | Japanese Encephalitis Virus Disease | 06/26 | 03/28 | | |
NCT05620940: A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects. |
|
|
| Recruiting | 1 | 40 | RoW | Vivitrol Injectable Product, IVL3004, IVL4002 | Inventage Lab., Inc. | Opioid Dependence, Alcohol Dependence | 05/25 | 05/25 | | |
NCT05831995: Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors. |
|
|
| Terminated | 1 | 12 | US | ABM-168 | ABM Therapeutics Corporation | Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation | 06/24 | 06/24 | | |
| Rogers, Jason |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 05/24 | 06/28 | | |
| Recruiting | N/A | 50 | Canada, US | Cephea Mitral Valve System | Abbott Medical Devices | Mitral Regurgitation | 03/26 | 03/31 | | |
| Fleming, Neal W |
NCT05478174: Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia |
|
|
| Completed | 3 | 400 | US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 11/23 | 11/23 | | |
NCT03075150: PVI as a Parameter to Predict Fluid Responsiveness |
|
|
| Recruiting | N/A | 100 | US | Masimo Rainbow sensor | University of California, Davis, Masimo Corporation | Surgery | 07/19 | 07/19 | | |
NCT04730063: Evaluation of Novel Cardio-Pulmonary Physiological Monitor, the VQm PHM™, for Acute Care Medicine |
|
|
| Recruiting | N/A | 40 | US | VQm PHM™ | Rostrum Medical Innovations Inc., University of California, Davis | Elective Procedures Requiring Mechanical Ventilation | 01/23 | 02/23 | | |
| Teirstein, Paul S |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
NCT03735667: ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement |
|
|
| Active, not recruiting | N/A | 1948 | Canada, US | ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System, ACURATE Prime™ Transfemoral TAVR System XL | Boston Scientific Corporation | Aortic Stenosis | 06/24 | 09/34 | | |
| Underwood, Mark |
| Active, not recruiting | N/A | 120 | US | Bifidobacterium, B. infantis | University of California, Davis, Evolve BioSystems, Inc. | Healthy | 07/16 | 06/27 | | |
| Yoneda, Ken |
| Active, not recruiting | N/A | 210 | Europe, US | RejuvenAir System, Sham Control Procedure | CSA Medical, Inc. | Chronic Bronchitis | 05/25 | 09/26 | | |
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis |
|
|
| Active, not recruiting | N/A | 270 | Europe, US | RheOx Bronchial Rheoplasty, Sham Procedure | Gala Therapeutics, Inc. | Chronic Bronchitis | 05/24 | 10/25 | | |
| Active, not recruiting | N/A | 464 | Europe, US | Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care | Nuvaira, Inc. | COPD | 10/24 | 09/28 | | |
| Bold, Richard J |
| Recruiting | 2/3 | 1912 | Canada, US | Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month | NRG Oncology, Natera, Inc., National Cancer Institute (NCI) | Stage III Colon Cancer | 03/29 | 03/30 | | |
| Huang, Susan |
NCT05714969 / 2022-001940-36: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) |
|
|
| Active, not recruiting | 2 | 40 | Europe, US, RoW | TAK-755, rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930 | Takeda, Takeda Development Center Americas, Inc. | Thrombotic Thrombocytopenic Purpura (TTP) | 03/25 | 03/25 | | |
NCT06386874: EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment |
|
|
| Recruiting | N/A | 122 | US | Q Therapeutic System (BQ 3.0) - Sham, BQ 3.0 Sham Stimulation Group, Q Therapeutic System (BQ 3.0) - Active, BQ 3.0 Active Stimulation Group Interventions | BrainQ Technologies Ltd. | Ischemic Stroke | 07/26 | 10/26 | | |
| May, Larissa S |
SEPSIS-SHIELD, NCT04094818: TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis |
|
|
| Completed | N/A | 1441 | Europe, US | TriVerity, InSep, HostDx Sepsis | Inflammatix | Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection, Suspected Meningitis/Encephalitis or Any Other Infection, Sepsis | 08/24 | 09/24 | | |
| Holmes, James F |
NCT03564795: Effectiveness of KeraStat Gel for Improved Cosmesis of Partial Thickness Burns |
|
|
| Terminated | N/A | 14 | US | KeraStat Gel, Silver Sulfadiazine, SSD | KeraNetics, LLC, Wake Forest University, United States Department of Defense | Partial-thickness Burn | 03/23 | 03/23 | | |
| Smilowitz, Jennifer T |
| Active, not recruiting | N/A | 120 | US | Bifidobacterium, B. infantis | University of California, Davis, Evolve BioSystems, Inc. | Healthy | 07/16 | 06/27 | | |
| Wang-Polagruto, Janice |
NCT03118505: A Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions |
|
|
| Active, not recruiting | N/A | 100 | US | Infuse Bone Graft, Medtronic DBM | Medtronic Spinal and Biologics | Multi-Level Degenerative Lumbosacral Spinal Conditions | 04/26 | 12/26 | | |
| Recruiting | N/A | 1017 | US, RoW | Infuse™ Bone Graft (Infuse™), Intervertebral body fusion device and Medtronic posterior Fixation Systems | Medtronic Spinal and Biologics | Degenerative Disease of the Lumbosacral Spine | 04/26 | 04/28 | | |
| Recruiting | N/A | 1000 | US | Follow-up schedule: pre-operative baseline up to 24-months post-procedure | Medtronic Spinal and Biologics, Medtronic Bakken Research Center | Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma, Spinal Tumor Case | 05/31 | 05/31 | | |
| Adams, Christopher |
| Terminated | N/A | 12500 | Europe, Canada, US, RoW | | Arthrex, Inc. | Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip | 07/23 | 07/23 | | |
| Ament, Jared |
| Recruiting | N/A | 200 | US | Lumbar Interbody Fusion | 3Spine, MCRA | Lumbar Spine Degeneration | 05/24 | 08/26 | | |
NCT05740176: The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery |
|
|
| Active, not recruiting | N/A | 200 | US | Anterior Cervical Discectomy and Fusion, ACDF | Synergy Spine Solutions, MCRA | Cervical Degenerative Disc Disease | 09/26 | 12/26 | | |
NCT05438719: MOTUS Total Joint Replacement Investigational Device Exemption Study |
|
|
| Active, not recruiting | N/A | 158 | US | MOTUS Total Joint Replacement | 3Spine | Lumbar Spine Degeneration | 06/25 | 06/28 | | |
| Thompson, George H |
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole |
|
|
| Suspended | 3 | 220 | Europe, Canada, US, RoW | SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin | Scynexis, Inc., SCYNEXIS, Inc. | Candidiasis, Invasive, Candidemia | 06/24 | 08/24 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
| Completed | 2 | 203 | Europe, US, RoW | Olorofim, F901318 | F2G Biotech GmbH, Iqvia Pty Ltd | Invasive Fungal Infections | 02/23 | 02/23 | | |
| Jr, James A McNamara |
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Active, not recruiting | 3 | 160 | Europe, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic | 08/24 | 09/25 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
NCT03977467: Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor |
|
|
| Completed | 2 | 46 | US | Atezolizumab, TECENTRIQ, Chemotherapy (Arm A Only), Tiragolumab | SCRI Development Innovations, LLC, Genentech, Inc. | Non-Small Cell Lung Cancer, Solid Tumor | 08/24 | 08/24 | | |
NCT04392635: Device to Assist With Abdominal Access During Laparoscopic Surgery |
|
|
| Completed | N/A | 30 | US | TauTona Pneumoperitoneum Assist Device (TPAD), Standard of Care (SOC) | Stanford University, TauTona Group | Laparoscopic Surgery | 06/24 | 06/24 | | |
| Recruiting | N/A | 1200 | US | Observation | Tempus AI, AstraZeneca | Non-Small Cell Lung Cancer | 06/29 | 06/29 | | |
| Maselli, Ricardo |
NCT06436742: A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants with DOK7-Congenital Myasthenic Syndromes (CMS) |
|
|
| Recruiting | 1 | 15 | Europe, Canada, US | ARGX-119, Placebo | argenx | Congenital Myasthenic Syndrome | 10/25 | 10/25 | | |
NCT03062631: Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia |
|
|
| No Longer Available | N/A | | US | 3,4-Diaminopyridine, 3,4-DAP | Ricardo Maselli, Catalyst Pharmaceuticals, Inc. | Congenital Myasthenic Syndrome | | | | |
| Maverakis, Emanual |
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color |
|
|
| Active, not recruiting | 3 | 80 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 05/24 | 02/25 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
| Lee, Darrin |
NCT03622905: ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease |
|
|
| Completed | N/A | 74 | Europe, Canada, US | DBS-f On, DBS Off | Functional Neuromodulation Ltd | Alzheimer Disease | 02/24 | 02/24 | | |
| Coordinator, Site |
NCT05069597: Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon |
|
|
| Completed | 4 | 30 | US | CREON, Pancrelipase | AbbVie | Cystic Fibrosis, Chronic Pancreatitis | 07/23 | 08/23 | | |
NCT05647551: A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections |
|
|
| Completed | 4 | 73 | Europe, RoW | BOTOX®/VISTABEL®, Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine, Juvéderm® VOLUMA® with Lidocaine | AbbVie | Facial Corrections, Facial Lines | 10/23 | 10/23 | | |
NCT01192568: Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder |
|
|
| Completed | 4 | 52 | US | Oxybutynin, Gelnique, Placebo | AbbVie | Overactive Detrusor, Neurogenic Bladder | 08/23 | 10/23 | | |
NCT06218251: A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines |
|
|
| Completed | 4 | 100 | Canada, US | BOTOX, Botulinum Toxin Type A, OnabotulinumtoxinA | AbbVie | Upper Facial Lines | 07/24 | 12/24 | | |
IMMpactful, NCT06333860: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) |
|
|
| Active, not recruiting | 4 | 393 | Europe, Canada, US, RoW | Risankizumab, Deucravacitinib | AbbVie | Moderate Plaque Psoriasis | 03/25 | 03/26 | | |
NCT05969223: Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis |
|
|
| Active, not recruiting | 4 | 214 | US | Risankizumab, Skyrizi, ABBV-066, Placebo for Risankizumab | AbbVie | Genital Psoriasis, Scalp Psoriasis | 01/25 | 10/25 | | |
| Completed | 4 | 461 | Europe, Canada, Japan, RoW | Upadacitinib, RINVOQ, ABT-494 | AbbVie, AbbVie Inc. | Atopic Dermatitis | 07/24 | 08/24 | | |
VIALE-M, NCT04102020 / 2019-002217-19: A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy |
|
|
| Active, not recruiting | 3 | 112 | Europe, Canada, Japan, US, RoW | Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine | AbbVie, Roche-Genentech | Acute Myeloid Leukemia (AML) | 09/22 | 04/25 | | |
NCT04994535 / 2021-000240-22: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence |
|
|
| Completed | 3 | 426 | Europe, Canada, US | OnabotulinumtoxinA, BOTOX, Placebo | AbbVie, AbbVie Inc. | Platysma Prominence | 06/23 | 06/23 | | |
NCT05139121: Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles |
|
|
| Completed | 3 | 1319 | Canada, US | MR-100A-01, Transdermal contraceptive delivery system | Mylan Technologies Inc., Mylan Inc. | Contraception | 01/25 | 01/25 | | |
NCT02814916 / 2014-005281-30: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA |
|
|
| Completed | 3 | 199 | Europe, US, RoW | Dalbavancin, Xydalba, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin | AbbVie | Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections | 01/24 | 01/24 | | |
NCT06174688: A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants |
|
|
| Completed | 3 | 140 | RoW | BOTOX, Botulinum Toxin Type A, Placebo | AbbVie | Forehead Lines | 09/24 | 09/24 | | |
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma |
|
|
| Recruiting | 3 | 1080 | Europe, Japan, US, RoW | Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine | Genmab, AbbVie | Follicular Lymphoma (FL) | 11/37 | 11/37 | | |
| Active, not recruiting | 3 | 429 | Europe, Canada, Japan, US, RoW | Upadacitinib, ABT-494, RINVOQ, Corticosteroid (CS), Placebo | AbbVie | Giant Cell Arteritis (GCA) | 02/24 | 03/25 | | |
|
|
|
|
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) |
|
|
| Completed | 3 | 286 | Europe, Canada, US, RoW | Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret | AbbVie | Hepatitis C Virus (HCV) | 09/24 | 09/24 | | |
Level Up, NCT05601882 / 2022-002482-15: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 926 | Europe, Canada, Japan, US, RoW | Upadacitinib, RINVOQ, Dupilumab | AbbVie, AbbVie Inc. | Atopic Dermatitis | 03/24 | 08/24 | | |
NCT06387394: A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence |
|
|
| Active, not recruiting | 3 | 202 | US | BOTOX, OnabotulinumtoxinA, Placebo | AbbVie | Masseter Muscle Prominence | 12/25 | 12/25 | | |
NCT06158841: Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 3 | 380 | Europe, Japan, US, RoW | Etentamig, ABBV-383, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone | AbbVie | Multiple Myeloma | 12/27 | 12/27 | | |
Switch-Up, NCT06389136: A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab |
|
|
| Recruiting | 3 | 300 | Japan, US, RoW | Upadacitinib Dose A, ABT-494, RINVOQ, Dupilumab Dose A, Upadacitinib Dose B | AbbVie | Atopic Dermatitis | 08/25 | 03/26 | | |
NCT06468228: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Recruiting | 3 | 1280 | Europe, Canada, Japan, US, RoW | Lutikizumab, ABT-981, Placebo | AbbVie | Hidradenitis Suppurativa | 12/26 | 12/26 | | |
| Completed | 3 | 775 | Europe, Canada, US, RoW | BOTOX, Botulinum Toxin Type A, Placebo | AbbVie | Episodic Migraine | 11/24 | 11/24 | | |
|
NCT06428019: A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) |
|
|
| Recruiting | 3 | 120 | Europe, US, RoW | Venetoclax, ABT-199, Acalabrutinib, Obinutuzumab | AbbVie | Chronic Lymphocytic Leukemia | 10/26 | 10/26 | | |
EPCORE DLBCL-4, NCT06508658: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 320 | Europe, Japan, US, RoW | Epcoritamab, ABBV-GMAB-3013, Epkinly, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine | Genmab | Diffuse Large B-Cell Lymphoma | 01/28 | 01/28 | | |
TRANSFORM-2, NCT04468984 / 2020-000557-27: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis |
|
|
| Active, not recruiting | 3 | 295 | Europe, Canada, Japan, US, RoW | Navitoclax, ABT-263, Ruxolitinib, Best Available Therapy (BAT) | AbbVie | Myelofibrosis (MF) | 02/25 | 12/26 | | |
|
|
Start Up, NCT06461897: A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 675 | Europe, Canada, US, RoW | Upadacitinib, ABT-494, RINVOQ®, RINVOQ LQ, Dupilumab | AbbVie | Atopic Dermatitis | 07/30 | 07/30 | | |
UBRO MM, NCT06417775: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine |
|
|
| Recruiting | 3 | 450 | US | Ubrogepant, UBRELVY, Placebo for Ubrogepant | AbbVie | Migraine | 09/27 | 09/27 | | |
NCT05316220: A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis |
|
|
| Not yet recruiting | 3 | 80 | US | Mesalamine, Delzicol, Placebo | AbbVie | Ulcerative Colitis (UC) | 07/26 | 07/26 | | |
LINZESS, NCT04026113 / 2019-001500-38: Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) |
|
|
| Completed | 3 | 438 | Europe, Canada, US, RoW | Linaclotide, Placebo | AbbVie, Ironwood Pharmaceuticals, Inc. | Functional Constipation, Irritable Bowel Syndrome With Constipation | 05/24 | 05/24 | | |
| Completed | 3 | 150 | Europe, Canada, Japan, US | Risankizumab, SKYRIZI, ABBV-066, Ustekinumab | AbbVie | Psoriasis | 02/24 | 10/24 | | |
NCT05439616: Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD |
|
|
| Completed | 3 | 161 | US | Cariprazine, VRAYLAR, AGN-241780, Placebo | AbbVie | Autism Spectrum Disorder | 10/24 | 10/24 | | |
NCT05652205: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation |
|
|
| Active, not recruiting | 3 | 123 | Europe, US | Linaclotide, Placebo for Linaclotide | AbbVie, Ironwood Pharmaceuticals, Inc. | Functional Constipation (FC), Chronic Idiopathic Constipation (CIC) | 08/25 | 11/25 | | |
NCT06629597: A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 3 | 400 | RoW | YL201, Docetaxel, Capecitabine, Gemcitabine | MediLink Therapeutics (Suzhou) Co., Ltd. | Nasopharyngeal Carcinoma | 12/27 | 12/28 | | |
NCT06612151: A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 438 | RoW | YL201, topotecan hydrochloride for injection | MediLink Therapeutics (Suzhou) Co., Ltd. | Small Cell Lung Cancer | 12/27 | 12/30 | | |
ELARIS EM-COC, NCT04333576: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain |
|
|
| Recruiting | 3 | 800 | US | Elagolix, ABT-620, Orilissa, Placebo, Combined Oral Contraceptive | AbbVie | Endometriosis | 03/29 | 06/30 | | |
NCT05216263: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine |
|
|
| Active, not recruiting | 3 | 75 | US | Atogepant, QULIPTA | AbbVie | Chronic Migraine | 04/25 | 04/25 | | |
NCT05316233: A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants |
|
|
| Completed | 3 | 159 | US | VOLITE XC, JUVÉDERM® VOLITE™ XC | AbbVie | Neck Lines | 09/24 | 09/24 | | |
NCT05452070: A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants |
|
|
| Active, not recruiting | 3 | 171 | Europe, Canada | HArmonyCa Lidocaine Injectable Gel | Allergan | Mid Face Volume Deficit | 05/25 | 05/25 | | |
Up-AA, NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 1399 | Europe, Canada, Japan, US, RoW | Upadacitinib, Rinvoq, ABT-494, Placebo | AbbVie | Alopecia Areata | 01/28 | 01/28 | | |
